Why This Small-Cap Stock Is Gaining More Than 10% Today?

Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18. Immuneering’s lead candidate, IMM-1-104, an…
  • Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18.
  • Immuneering’s lead candidate, IMM-1-104, an oral MEK inhibitor, is on track for 3Q22 IND filing, with potential for data 12-18 months later. 
  • Chardan summarized the drivers as follows:
    • IMM-1-104’s CRAF bypass prevention mechanism and ~2-hour half-life differentiate it from approved and clinical-stage MEK inhibitors.
    • Initial focus on biomarker-defined populations with high unmet need increase the chances of seeing a clear activity signal and favorable benefit/risk profile.
    • If Immuneering’s “deep cyclic inhibition” strategy does translate to better tolerability, IMM-1-104 could be attractive as a backbone in combination regimens targeting other MAPK nodes or parallel pathways.
    • Proof-of-concept for IMM-1-104 and the translational bioinformatics platform could attract partnership interest for other pipeline programs.
  • Price Action: IMRX shares are up 11.30% at $6.29 during the market session on the last check Friday.
Total
0
Shares
Related Posts
Read More

What’s Going On With Facebook Parent Meta Platforms’ Stock?

Jefferies analyst Brent Thill maintained a Buy rating on Meta and raised the price target from $550 to $585 Thursday. Wells Fargo maintained an Overweight rating and lowered its price target from $609 to $600 Wednesday. Meta is set to announce its first-quarter financial results after the market close on April 24 and will host a conference call to discuss the results at 5 p.m. ET the same day. According to estimates from Benzinga Pro, the company is expected to report earnings of $4.28 per share and quarterly revenue of $36.051 billion.

META